The group will need longer-term data to justify its huge valuation.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.